Pharmaceuticals

Neurological Disorder Drugs Market Future Outlook: Strong Growth Expected Toward $116.27 Billion by 2030

February 17, 2026February 17, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the neurological disorder drugs market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Neurological Disorder Drugs Market by the end of 2030?

The neurological disorder drugs market size has experienced robust expansion in recent years. Projections indicate an increase from $89.24 billion in 2025 to $94.49 billion by 2026, demonstrating a compound annual growth rate (CAGR) of 5.9%. This historical growth can be linked to several key factors, including the increasing occurrence of epilepsy and neurodegenerative conditions, a globally aging population, the sustained usage of symptomatic neurological medications, the broadened availability of hospital-based neurological services, and improved detection rates for neurological disorders.

The neurological disorder drugs market is projected to experience substantial expansion over the upcoming years. This market is set to reach $116.27 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.3%. This anticipated growth during the forecast period is primarily driven by progress in neurological drug development pipelines, the increasing prevalence of Alzheimer’s and Parkinson’s disease, improved availability of neurological care in emerging markets, a growing need for personalized neurology treatments, and the expansion of homecare and outpatient neurological therapy. Key trends for the forecast period encompass the increasing embrace of disease-modifying neurological therapies, a heightened focus on early diagnosis and ongoing disease management, a surge in demand for combination drug therapies, the proliferation of oral and home-based neurological treatments, and a greater emphasis on symptom alleviation and enhancing the quality of life.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

What Drivers Are Shaping Future Opportunities In The Neurological Disorder Drugs Market?

The escalating occurrence of neurological diseases is anticipated to drive the growth of the neurological disorder drugs market in the future. Neurological disorders encompass conditions impacting the brain, spinal cord, and nerves, arising from structural, biochemical, or electrical abnormalities, which lead to diverse symptoms. The rise in neurological diseases can be attributed to an aging global population and increased exposure to environmental, metabolic, and lifestyle risk factors. Medications for neurological disorders are crucial in managing these complex conditions, offering symptomatic relief, slowing disease progression, and improving long-term outcomes for patients. For instance, in September 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, it is projected that the number of people living with dementia in Australia will more than double between 2023 and 2058, increasing from approximately 411,100 in 2023 to 849,300 by 2058, with around 315,500 men and 533,800 women affected. Consequently, the rising prevalence of neurological disease is fueling the expansion of the neurological disorder drugs market.

Which Segments Are Gaining Traction In The Neurological Disorder Drugs Market?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

What Trends Are Reshaping The Dynamics Of The Neurological Disorder Drugs Market?

Leading companies in the neurological disorder drugs market are actively engaged in developing innovative solutions, such as Ocrelizumab-based therapies, to enhance treatment effectiveness, improve patient outcomes, and broaden therapeutic alternatives for individuals suffering from multiple sclerosis. Ocrelizumab is a humanized monoclonal antibody specifically engineered to target CD20-positive B cells, thereby assisting in the reduction of disease activity and the deceleration of progression in both relapsing and primary progressive forms of multiple sclerosis. For instance, in September 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, obtained regulatory approval from the U.S. Food and Drug Administration (FDA) for OCREVUS ZUNOVO (ocrelizumab & hyaluronidase-ocsq). This product is a twice-yearly, approximately 10-minute subcutaneous injection, marking it as the first-ever subcutaneous Ocrevus formulation approved for both relapsing (RMS) and primary progressive (PPMS) multiple sclerosis. This advanced delivery option is designed to improve patient convenience, expand access to therapy, and bolster clinical workflow efficiency by offering a quicker, non-intravenous administration method.

Who Are The Top-Performing Companies In The Neurological Disorder Drugs Market In Recent Years?

Major companies operating in the neurological disorder drugs market are F. Hoffmann-La Roche Ltd, Bayer AG, Sanofi S.A, AstraZeneca PLC, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company Pvt Ltd, Amgen Inc, Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd, Otsuka America Pharmaceutical Inc, Biogen Inc, Bausch Health Companies Inc, Alexion Pharmaceuticals Inc., UCB S.A., Eisai Co Ltd, Cipla Inc, BioMarin Pharmaceutical Inc., Biocon Ltd, Acorda Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Which Region Currently Holds The Largest Share Of The Neurological Disorder Drugs Market?

North America was the largest region in the neurological disorder drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Neurological Disorder Drugs Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Browse Through More Reports Similar to the Global Neurological Disorder Drugs Market 2026, By The Business Research Company

Neurological Disorder Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

Central Nervous System Drug Market Report 2026

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Cholinergic Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/cholinergic-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795